31 Results for "

Aβ42 aggregation

" in MedChemExpress (MCE) Product Catalog:
Products (31)

31 Results for "Aβ42 aggregation" in MCE Product Catalog:

12
12 Publications Verification
Cat. No.: HY-N0373
CAS No.: 58749-23-8
Licochalcone B is an extract from the root of Glycyrrhiza uralensis. Licochalcone B inhibits amyloid β (42) self-aggregation (IC50=2.16 μM) and disaggregate pre-formed Aβ42 fibrils, reduce metal-induced Aβ42 aggregation through chelating metal ionsLicochalcone B inhibits phosphorylation of NF-κB p65 in LPS signaling pathway. Licochalcone B inhibits growth and induces apoptosis of NSCLC cells. Licochalcone B specifically inhibits the NLRP3 inflammasome by disrupting NEK7‐NLRP3 interaction .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-B0364A
CAS No.: 536-43-6
Synonyms: Dyclocaine hydrochloride
Dyclonine hydrochloride (Dyclocaine hydrochloride) is an orally active, blood-brain barrier-permeable piperidine phenylacetone small molecule commonly used as a local anesthetic. Dyclonine hydrochloride acts as a highly selective allosteric antagonist of TRPV3; it also reversibly inhibits G9a, ALDH2 and ALDH3A1, non-competitively blocks AChE. Dyclonine hydrochloride activates the Nrf2/ARE pathway, relieves the epigenetic silencing of FXN, blocks Aβ42 aggregation, and promotes remyelination and reparative polarization of microglia. Dyclonine hydrochloride alleviates pruritus via TRPV3 inhibition; it is used in studies of neurodegenerative disease models based on its AChE inhibitory, antioxidant and remyelinating effects; it sensitizes drug-resistant tumors through ALDH inhibition, and combined use with protease inhibitors induces more tumor cell apoptosis; it inhibits Candida albicans in vitro. Dyclonine hydrochloride can be used for research on multiple diseases including neurodegenerative diseases, cancer and pruritic dermatitis .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-N11077
CAS No.: 89886-30-6
Synonyms: 4,5-di-O-CQA
4,5-Di-O-caffeoylquinic acid (4,5-di-O-CQA) is a natural product with multiple activities including anti-inflammatory, antioxidant, and antibacterial properties. 4,5-Di-O-caffeoylquinic acid induces intracellular Ca 2+ influx, and inhibits hypoxia-induced COX-2 expression and cell migration via the TRPV1-mediated pathway. 4,5-Di-O-caffeoylquinic acid scavenges DPPH free radicals, inhibits Cu 2+-mediated LDL oxidation, and reduces the production of TBARS. 4,5-Di-O-caffeoylquinic acid promotes intracellular ATP production, inhibits Aβ42 aggregation and β-sheet conversion, and protects neuroblastoma cells. 4,5-Di-O-caffeoylquinic acid inhibits the growth of Bacillus shigae. 4,5-Di-O-caffeoylquinic acid can be used in studies related to atherosclerosis, Alzheimer's disease, and bacterial infections .
loading...
    loading...
Cat. No.: HY-114508
CAS No.: 1083-30-3
Purity:  99.87%
Synonyms: 3-Phenylpropiophenone; β-Phenylpropiophenone
Target:  

Amyloid-β

Research Areas:  

Neurological Disease

Dihydrochalcone (3-Phenylpropiophenone) is a aggregation inhibitor. Dihydrochalcone destabilizes Aβ17-42 protofibrils by disrupting the β-sheet of β1 region. Dihydrochalcone destabilizes both U-shaped Aβ40/Aβ42 protofibrils and S-shaped Aβ42 protofibrils by binding to the protofibril cavity. Dihydrochalcone is the main component of daemonorops draco tree .
loading...
    loading...
Cat. No.: HY-149764
CAS No.: 6314-40-5
Purity:  99.92%
Target:  

Amyloid-β

Research Areas:  

Neurological Disease

Aβ42 agonist-2 (compound 7b) is a small molecule compound that can promote Aβ42 aggregation. Aβ42 agonist-2 can interact with Aβ42 oligomers and pentamers to promote nontoxic aggregate self-assembly and rapid fibril formation. Aβ42 agonist-2 prevents Aβ42-induced cytotoxicity in HT22 hippocampal neuronal cells .
loading...
    loading...
Cat. No.: HY-121815
CAS No.: 956128-08-8
Target:  

Amyloid-β

Research Areas:  

Neurological Disease

TDI-2760 is an aggregation inhibitor with an IC50 of 1.67 μM. TDI-2760 can inhibit the Aβ-fibrinogen interaction and Aβ aggregation, and also modulate the contact system activation induced by Aβ42. TDI-2760 can be used in research related to vascular abnormalities and Aβ aggregation in Alzheimer's disease .
loading...
    loading...
Cat. No.: HY-P3846
CAS No.: 1802086-22-1
Target:  

Amyloid-β

Research Areas:  

Neurological Disease

(Glu20)-Amyloid β-Protein (1-42) is a slower fibrillizing variant of amyloid β-protein (Aβ). The Glu20 mutation reduces the aggregation propensity of Aβ42 and prevents accumulation of the slowly fibrillizing peptide. Amyloid β-protein is the primary component of both vascular and parenchymal amyloid deposits in Alzheimer's disease .
loading...
    loading...
Cat. No.: HY-149763
CAS No.: 50635-12-6
Purity:  99.90%
Target:  

Amyloid-β

Research Areas:  

Neurological Disease

Aβ42 agonist-1 is a compound that can promote Aβ42 aggregation. Aβ42 agonist-1 can interact with Aβ42 oligomers and pentamers to promote nontoxic aggregate self-assembly and rapid fibril formation. Aβ42 agonist-1 prevents Aβ42-induced cytotoxicity in HT22 hippocampal neuronal cells .
loading...
    loading...
Cat. No.: HY-146139
CAS No.: 2477606-87-2
Target:  

Amyloid-β

Research Areas:  

Neurological Disease

Aβ-IN-3 (compound 1) is a potent amyloid β (Aβ) inhibitor. Aβ-IN-3 inhibits Aβ42 aggregation. However, Aβ-IN-3 can not alleviate the neurotoxicity of Aβ42 in SH-SY5Y cells. Aβ-IN-3 can not change the aggregation state of Aβ42 into a nontoxic one .
loading...
    loading...
Cat. No.: HY-146140
CAS No.: 2477606-97-4
Target:  

Amyloid-β

Research Areas:  

Neurological Disease

Aβ-IN-4 (compound 12) is a potent amyloid β (Aβ) inhibitor. Aβ-IN-4 inhibits Aβ42 aggregation. However, Aβ-IN-4 can not alleviate the neurotoxicity of Aβ42 in SH-SY5Y cells. Aβ-IN-4 can not change the aggregation state of Aβ42 into a nontoxic one .
loading...
    loading...
Cat. No.: HY-P10876
Target:  

Amyloid-β

Research Areas:  

Neurological Disease

mcK6A1 is an inhibitor for the aggregation of amyloid-β (), that selectively binds to the 16KLVFFA21 segment of Aβ42, forms an extended β-folded structure, and inhibits the formation of Aβ42 oligomers. mcK6A1 can be used in research of Alzheimer's disease and other amyloid-related diseases .
loading...
    loading...
Cat. No.: HY-N0373R
CAS No.: 58749-23-8
Licochalcone B (Standard) is the analytical standard of Licochalcone B. This product is intended for research and analytical applications. Licochalcone B is an extract from the root of Glycyrrhiza uralensis. Licochalcone B inhibits amyloid β (42) self-aggregation (IC50=2.16 μM) and disaggregate pre-formed Aβ42 fibrils, reduce metal-induced Aβ42 aggregation through chelating metal ionsLicochalcone B inhibits phosphorylation of NF-κB p65 in LPS signaling pathway. Licochalcone B inhibits growth and induces apoptosis of NSCLC cells. Licochalcone B specifically inhibits the NLRP3 inflammasome by disrupting NEK7‐NLRP3 interaction .
loading...
    loading...
Cat. No.: HY-146251
CAS No.: 2003213-07-6
Research Areas:  

Neurological Disease

BuChE-IN-6 (compound 1b) is a potent and selective BuChE (butyrylcholinesterase) inhibitor, with IC50 values of 0.46 and 0.51 μM for eqBuChE and hBuChE, respectively. BuChE-IN-6 also inhibits Aβ42 self-aggregation .
loading...
    loading...
Cat. No.: HY-N12321
CAS No.: 54299-64-8
2',3'-Dihydroxy-4',6'-dimethoxychalcone (compound 1) can inhibit Amyloid β-protein (Aβ42) fibrillization and aggregation. 2',3'-Dihydroxy-4',6'-dimethoxychalcone has oral activity and can be detected in the brain .
loading...
    loading...
Cat. No.: HY-162832
Target:  

Amyloid-β

Research Areas:  

Neurological Disease

Amyloid-β-IN-1 (compound 13) is a synthetic peptide containing the hydrophobic C-terminal region "VVIA-NH2" and its reverse sequence "AIVV-NH2" of Aβ42, which is an inhibitor. Amyloid-β-IN-1 can inhibit Aβ aggregation and has neuroprotective effects .
loading...
    loading...
Cat. No.: HY-173144
AChE-IN-85 (Compound 7k) is an AChE inhibitor with an IC50 of 0.083 μM. AChE-IN-85 can inhibit the release of NO, the production of TNF-α and IL-1β, the levels of LDH and ROS, as well as the aggregation of Aβ42. AChE-IN-85 has anti-inflammatory and neuroprotective effects and can be used in the research of diseases such as Alzheimer's disease .
loading...
    loading...
Cat. No.: HY-175658
AChE/BChE-IN-29 is an AChE/BChE inhibitor. AChE/BChE-IN-29 exhibits balanced dual cholinesterase inhibitory activity with IC50 values of 2.1 μM for Electrophorus electricus AChE (eeAChE) and 6.3 μM for equine serum butyrylcholinesterase (eqBChE). AChE/BChE-IN-29 effectively inhibits amyloid-β (Aβ42) aggregation and tau protein aggregation in E. coli cell models. AChE/BChE-IN-29 can be used for the study of Alzheimer’s disease (AD) .
loading...
    loading...
Cat. No.: HY-P10824
CAS No.: 1430219-69-4
Target:  

Amyloid-β

Research Areas:  

Neurological Disease

RI-OR2-TAT is a brain-penetrant inhibitor of β-Amyloid oligomerization, which is produced by adding the HIV protein transduction domain TAT to RI-OR2. RI-OR2-TAT binds to Aβ42 fibrils with a Kd value of 58-125 nM. RI-OR2-TAT reduces aggregation and plaque levels, reduces activation of microglia and oxidative damage, and increases the number of young neurons in the dentate gyrus .
loading...
    loading...
Cat. No.: HY-173282
Target:  

Amyloid-β

Research Areas:  

Neurological Disease

aggregation-IN-2 (Compound 8i) is an inhibitor of amyloid-β protein (Aβ42) aggregation, showing approximately 91% inhibition of Aβ42 aggregation at 25 μM. It also exhibits Aβ42 disaggregation effects and antioxidant activity. Aβ aggregation-IN-2 can be used for research in the field of Alzheimer's disease .
loading...
    loading...
Cat. No.: HY-169103
Neuroprotective agent 5 (compound 28) is a brain permeabilizing agent with anti-neuritis, anti-oxidative damage and neuroprotective effects. Neuroprotective agent 5 exhibits a potent NO inhibitory effect (EC50=0.49 μM), inhibits the release of proinflammatory factors PGE2 and TNF-α, downregulates the expression of iNOS and COX-2 proteins, and promotes the polarization of BV-2 cells from the proinflammatory M1 phenotype to the anti-inflammatory M2 phenotype. In addition, Neuroprotective agent 5 can also inhibit acetylcholinesterase (AChE) activity and Aβ42 aggregation in a dose-dependent manner. Neuroprotective agent 5 can be used for the study of Alzheimer's disease .
loading...
    loading...